PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportsallergic conjunctivitis
MeSH D003233 - allergic conjunctivitis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D006969:Immediate hypersensitivity
0 Companies
0 Drugs
Success rate
D003231:Conjunctivitis
D003233: 
Allergic conjunctivitis
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaKetorolac tromethamine Ketorolac Tromethamine  1997-05-16   
Prednisone Prednisone  1982-01-01   
Pseudoephedrine, Triprolidine Triphed  1984-05-17   
Pseudoephedrine, Triprolidine Triprolidine Pseudoephedrine  1984-12-12   
Azelastine, Fluticasone Azelastine Fluticasone  2025-04-08   
PadagisAzelastine Azelastine  2014-05-08   
Azelastine, Fluticasone Azelastine Fluticasone  2021-02-18   
Olopatadine Olopatadine  2017-01-31   
Loteprednol etabonate Loteprednol Etabonate  2024-07-10   
Glenmark PharmaceuticalsOlopatadine Olopatadine  2017-06-28   
Olopatadine, Mometasone furoate Ryaltris 2034-09-04 2022-01-13   
MylanAzelastine Astelin  1996-11-01   
Azelastine Astepro 2025-11-22 2008-10-15   
Bepotastine Bepotastine  2019-03-18   
Azelastine, Fluticasone Dymista 2023-06-13 2012-05-01   
Ketorolac tromethamine Ketorolac Tromethamine  1997-05-16   
Azelastine Optivar  2000-05-22   
Prednisone Prednisone  1982-01-01   
Johnson & JohnsonKetotifen Acuvue Theravision With Ketotifen 2028-03-27 2022-02-25   
GSKPseudoephedrine, Codeine, Triprolidine Actifed  1984-04-04   
RocheKetorolac tromethamine Toradol  1991-12-20   
Senores PharmaceuticalsKetorolac tromethamine Ketorolac Tromethamine  2022-03-23   
Bausch Health CompaniesOlopatadine Olopatadine  2017-12-05   
Ketotifen Alaway  2020-09-24   
Loteprednol etabonate Alrex  1998-03-09   
Bepotastine Bepreve 2023-07-30 2009-09-08   
Loteprednol etabonate Lotemax  1998-03-09   
Loteprednol etabonate Lotemax Sm 2036-01-26 2019-02-22   
Prednisone Prednisone  1982-01-01   
Tobramycin, Loteprednol etabonate Zylet  2004-12-14   
1
2
3
4
5
6
...
13
>
Clinical Trials
Historical Success Rate
Phase 1
67%
4/6
Phase 2
49%
19/39
Phase 3
83%
35/42
Approved: 21Overall Success rate: 27%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Taro Pharmaceutical
1
2
3
4
5
6
...
9
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use